Exelixis Inc. has announced that its partner Ipsen has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ regarding CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated neuroendocrine tumors. This recommendation is a crucial step towards obtaining final approval from the European Commission, expected in the coming months. The positive CHMP opinion follows the U.S. FDA's approval in March 2025, based on the phase 3 CABINET trial results. This development highlights the ongoing efforts to bring new treatment options to patients in Europe, addressing the need for effective therapies following disease progression.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。